Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 25

1.

Liquid Formulation of AbobotulinumtoxinA: A 6-Month, Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of a Single Treatment, Ready-to-Use Toxin for Moderate-to-Severe Glabellar Lines.

Ascher B, Rzany B, Kestemont P, Hilton S, Heckmann M, Bodokh I, Noah EM, Boineau D, Kerscher M, Volteau M, Le Berre P, Picaut P.

Aesthet Surg J. 2019 Mar 20. pii: sjz003. doi: 10.1093/asj/sjz003. [Epub ahead of print]

PMID:
30893430
2.

Correction: Field, M. et al. AbobotulinumtoxinA (Dysport®), OnabotulinumtoxinA (Botox®), and IncobotulinumtoxinA (Xeomin®) Neurotoxin Content and Potential Implications for Duration of Response in Patients.

Field M, Splevins A, Picaut P, van der Schans M, Langenberg J, Noort D, Snyder D, Foster K.

Toxins (Basel). 2019 Feb 13;11(2). pii: E115. doi: 10.3390/toxins11020115.

3.

AbobotulinumtoxinA (Dysport®), OnabotulinumtoxinA (Botox®), and IncobotulinumtoxinA (Xeomin®) Neurotoxin Content and Potential Implications for Duration of Response in Patients.

Field M, Splevins A, Picaut P, van der Schans M, Langenberg J, Noort D, Foster K.

Toxins (Basel). 2018 Dec 13;10(12). pii: E535. doi: 10.3390/toxins10120535. Erratum in: Toxins (Basel). 2019 Feb 13;11(2):.

4.

Comment on: Botulinum Toxin Type A Overdoses: Analysis of the FDA Adverse Event Reporting System Database.

Picaut P.

Clin Drug Investig. 2018 Dec;38(12):1197-1198. doi: 10.1007/s40261-018-0723-4. No abstract available.

5.

The Expanding Therapeutic Utility of Botulinum Neurotoxins.

Fonfria E, Maignel J, Lezmi S, Martin V, Splevins A, Shubber S, Kalinichev M, Foster K, Picaut P, Krupp J.

Toxins (Basel). 2018 May 18;10(5). pii: E208. doi: 10.3390/toxins10050208. Review.

6.

AbobotulinumtoxinA Efficacy and Safety in Children With Equinus Foot Previously Treated With Botulinum Toxin.

Dabrowski E, Bonikowski M, Gormley M, Volteau M, Picaut P, Delgado MR.

Pediatr Neurol. 2018 May;82:44-49. doi: 10.1016/j.pediatrneurol.2017.12.013. Epub 2018 Feb 7.

PMID:
29625849
7.

Efficacy and safety of abobotulinumtoxinA in spastic lower limb: Randomized trial and extension.

Gracies JM, Esquenazi A, Brashear A, Banach M, Kocer S, Jech R, Khatkova S, Benetin J, Vecchio M, McAllister P, Ilkowski J, Ochudlo S, Catus F, Grandoulier AS, Vilain C, Picaut P; International AbobotulinumtoxinA Adult Lower Limb Spasticity Study Group.

Neurology. 2017 Nov 28;89(22):2245-2253. doi: 10.1212/WNL.0000000000004687. Epub 2017 Nov 1.

8.

Safety and Efficacy of Repeat Open-Label AbobotulinumtoxinA Treatment in Pediatric Cerebral Palsy.

Delgado MR, Bonikowski M, Carranza J, Dabrowski E, Matthews D, Russman B, Tilton A, Velez JC, Grandoulier AS, Picaut P.

J Child Neurol. 2017 Nov;32(13):1058-1064. doi: 10.1177/0883073817729918. Epub 2017 Sep 15.

9.

Dose-Dependent Effects of AbobotulinumtoxinA (Dysport) on Spasticity and Active Movements in Adults With Upper Limb Spasticity: Secondary Analysis of a Phase 3 Study.

O'Dell MW, Brashear A, Jech R, Lejeune T, Marque P, Bensmail D, Ayyoub Z, Simpson DM, Volteau M, Vilain C, Picaut P, Gracies JM.

PM R. 2018 Jan;10(1):1-10. doi: 10.1016/j.pmrj.2017.06.008. Epub 2017 Jun 19.

PMID:
28634000
10.

Efficacy and Safety of AbobotulinumtoxinA (Dysport) for the Treatment of Hemiparesis in Adults With Upper Limb Spasticity Previously Treated With Botulinum Toxin: Subanalysis From a Phase 3 Randomized Controlled Trial.

Marciniak C, McAllister P, Walker H, Brashear A, Edgley S, Deltombe T, Khatkova S, Banach M, Gul F, Vilain C, Picaut P, Grandoulier AS, Gracies JM; International AbobotulinumtoxinA Adult Upper Limb Spasticity Study Group.

PM R. 2017 Dec;9(12):1181-1190. doi: 10.1016/j.pmrj.2017.06.007. Epub 2017 Jun 16.

11.

Effects of repeated abobotulinumtoxinA injections in upper limb spasticity.

Gracies JM, O'Dell M, Vecchio M, Hedera P, Kocer S, Rudzinska-Bar M, Rubin B, Timerbaeva SL, Lusakowska A, Boyer FC, Grandoulier AS, Vilain C, Picaut P; International AbobotulinumtoxinA Adult Upper Limb Spasticity Study Group.

Muscle Nerve. 2018 Feb;57(2):245-254. doi: 10.1002/mus.25721. Epub 2017 Aug 13.

12.

Liquid Formulation of AbobotulinumtoxinA Exhibits a Favorable Efficacy and Safety Profile in Moderate to Severe Glabellar Lines: A Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Trial.

Ascher B, Kestemont P, Boineau D, Bodokh I, Stein A, Heckmann M, Dendorfer M, Pavicic T, Volteau M, Tse A, Picaut P, Rzany B.

Aesthet Surg J. 2018 Feb 17;38(2):183-191. doi: 10.1093/asj/sjw272.

PMID:
28200002
13.

AbobotulinumtoxinA (Dysport®) Improves Function According to Goal Attainment in Children With Dynamic Equinus Due to Cerebral Palsy.

Tilton A, Russman B, Aydin R, Dincer U, Escobar RG, Kutlay S, Lipczyk Z, Velez JC, Grandoulier AS, Tse A, Picaut P, Delgado MR.

J Child Neurol. 2017 Apr;32(5):482-487. doi: 10.1177/0883073816686910. Epub 2017 Jan 9.

14.

Poster 485 Safety and Tolerability of AbobotulinumtoxinA (Dysport) in Children (2-17 Years) with Lower Limb Spasticity Due to Cerebral Palsy: A Pooled Analysis of 8 Clinical Trials.

Matthews D, Camba GC, Pascual-Pascual I, Tilton AH, Gormley M, Mahmood A, Picaut P, Snyder D, Delgado MR.

PM R. 2016 Sep;8(9S):S318. doi: 10.1016/j.pmrj.2016.07.403. Epub 2016 Sep 24. No abstract available.

PMID:
27673230
15.

Poster 288 Efficacy and Safety of Repeated AbobotulinumtoxinA Injections in Adults with Lower Limb Spasticity.

Gracies JM, Esquenazi A, Brashear A, Edgley SR, O'Dell M, Hedera P, Rubin BS, Picaut P.

PM R. 2016 Sep;8(9S):S254. doi: 10.1016/j.pmrj.2016.07.461. Epub 2016 Sep 24. No abstract available.

PMID:
27673046
16.

Efficacy and safety of abobotulinumtoxinA liquid formulation in cervical dystonia: A randomized-controlled trial.

Poewe W, Burbaud P, Castelnovo G, Jost WH, Ceballos-Baumann AO, Banach M, Potulska-Chromik A, Ferreira JJ, Bihari K, Ehler E, Bares M, Dzyak LA, Belova AN, Pham E, Liu WJ, Picaut P.

Mov Disord. 2016 Nov;31(11):1649-1657. doi: 10.1002/mds.26760. Epub 2016 Sep 21.

PMID:
27653448
17.

AbobotulinumtoxinA for Equinus Foot Deformity in Cerebral Palsy: A Randomized Controlled Trial.

Delgado MR, Tilton A, Russman B, Benavides O, Bonikowski M, Carranza J, Dabrowski E, Dursun N, Gormley M, Jozwiak M, Matthews D, Maciag-Tymecka I, Unlu E, Pham E, Tse A, Picaut P.

Pediatrics. 2016 Feb;137(2):e20152830. doi: 10.1542/peds.2015-2830. Epub 2016 Jan 26.

18.

Efficacy and safety of two administration modes of an intra-detrusor injection of 750 units dysport® (abobotulinumtoxinA) in patients suffering from refractory neurogenic detrusor overactivity (NDO): A randomised placebo-controlled phase IIa study.

Denys P, Del Popolo G, Amarenco G, Karsenty G, Le Berre P, Padrazzi B, Picaut P; Dysport Study Group.

Neurourol Urodyn. 2017 Feb;36(2):457-462. doi: 10.1002/nau.22954. Epub 2016 Jan 12.

PMID:
26756554
19.

Does Reduction of Number of Intradetrusor Injection Sites of aboBoNTA (Dysport®) Impact Efficacy and Safety in a Rat Model of Neurogenic Detrusor Overactivity?

Huynh Le Maux A, Pignol B, Behr-Roussel D, Blachon JL, Chabrier PE, Compagnie S, Picaut P, Bernabé J, Giuliano F, Denys P.

Toxins (Basel). 2015 Dec 17;7(12):5462-71. doi: 10.3390/toxins7124896.

20.

Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double-blind randomised controlled trial.

Gracies JM, Brashear A, Jech R, McAllister P, Banach M, Valkovic P, Walker H, Marciniak C, Deltombe T, Skoromets A, Khatkova S, Edgley S, Gul F, Catus F, De Fer BB, Vilain C, Picaut P; International AbobotulinumtoxinA Adult Upper Limb Spasticity Study Group.

Lancet Neurol. 2015 Oct;14(10):992-1001. doi: 10.1016/S1474-4422(15)00216-1. Epub 2015 Aug 26.

PMID:
26318836

Supplemental Content

Loading ...
Support Center